Gilead Sciences, Inc. (NASDAQ:GILD) Announces Quarterly Dividend of $0.82

Gilead Sciences, Inc. (NASDAQ:GILD) declared a quarterly dividend on Tuesday, August 4th. Shareholders of record on Tuesday, September 15th will be paid a dividend of 0.82 per share by the biopharmaceutical company on Tuesday, September 29th. This represents a c) dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Tuesday, September 15th.

Gilead Sciences has increased its dividend by an average of 0.0%per year over the last three years and has raised its dividend annually for the last 10 consecutive years. Gilead Sciences has a payout ratio of 38.5% meaning its dividend is sufficiently covered by earnings. Research analysts expect Gilead Sciences to earn $9.73 per share next year, which means the company should continue to be able to cover its $3.28 annual dividend with an expected future payout ratio of 33.7%.

Gilead Sciences Stock Up 3.1%

Shares of GILD opened at $135.25 on Wednesday. The stock has a 50 day moving average price of $129.58 and a 200 day moving average price of $136.11. Gilead Sciences has a one year low of $108.46 and a one year high of $157.29. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The stock has a market capitalization of $167.92 billion, a price-to-earnings ratio of 18.43 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.26) by $0.51. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. During the same quarter in the prior year, the company earned $2.01 EPS. Gilead Sciences’s revenue was up 10.6% compared to the same quarter last year. Equities research analysts forecast that Gilead Sciences will post -0.78 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the transaction, the chief financial officer directly owned 173,191 shares of the company’s stock, valued at $22,907,973.57. The trade was a 1.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the completion of the transaction, the chief executive officer directly owned 592,133 shares of the company’s stock, valued at approximately $77,160,851.23. The trade was a 2.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 82,000 shares of company stock worth $10,641,790 over the last ninety days. Corporate insiders own 0.30% of the company’s stock.

Institutional Trading of Gilead Sciences

Several hedge funds have recently modified their holdings of GILD. Strategic Investment Solutions Inc. IL purchased a new stake in Gilead Sciences during the 4th quarter worth about $25,000. Vermillion & White Wealth Management Group LLC grew its position in shares of Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 85 shares in the last quarter. Quattro Advisors LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $26,000. Wealth Preservation Advisors LLC raised its holdings in Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 81 shares in the last quarter. Finally, Ares Financial Consulting LLC purchased a new position in Gilead Sciences in the fourth quarter worth approximately $28,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.